Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19869291 | 0.90 | NLRP3 (0.80) | NLRP3CA2 | |
| SCHEMBL6553993 | 0.89 | NLRP3 (0.78) | NLRP3CA2 | |
| SCHEMBL6553324 | 0.88 | NLRP3 (1.00) | NLRP3CA2 | |
| SCHEMBL19505692 | 0.87 | NLRP3 (0.75) | NLRP3CA2 | |
| SCHEMBL19506036 | 0.86 | NLRP3 (0.74) | NLRP3CA2 | |
| SCHEMBL19505693 | 0.86 | NLRP3 (0.74) | NLRP3CA2 | |
| SCHEMBL18007584 | 0.85 | NLRP3 (0.65) | NLRP3CA2 | |
| SCHEMBL7612982 | 0.83 | NLRP3 (0.90) | NLRP3CA2 | |
| SCHEMBL29551325 | 0.82 | NLRP3 (0.74) | NLRP3CA2 | |
| SCHEMBL19505701 | 0.82 | NLRP3 (0.74) | NLRP3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487457-A1 | COMBINATION OF AN IL-1/18 INHIBITOR WITH A TNF INHIBITOR FOR THE TREATMENT OF INFLAMMATION | Pfizer Products Inc. (US) | 2004-12-22 | — | — | EP | claimed |
| EP-1270565-B1 | 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives | PFIZER (US) | 2004-06-30 | — | — | EP | claimed |
| US-20030143230-A1 | Combination of an IL-1/18 inhibitor with a TNF inhibitor for the treatment of inflammation | PFIZER INC. | 2003-07-31 | — | — | US | claimed |
| WO-2003045400-A1 | COMBINATION OF AN IL-1/18 INHIBITOR WITH A TNF INHIBITOR FOR THE TREATMENT OF INFLAMMATION | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | claimed |
| EP-1270565-A1 | 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives | PFIZER INC. (US) | 2003-01-02 | — | — | EP | claimed |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2024-12-05 | — | — | US | disclosed |
| CN-113582889-B | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2024-09-20 | — | — | CN | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-20220112159-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | UNIV QUEENSLAND (AU) | 2022-04-14 | — | — | US | disclosed |
| CN-113582889-A | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2021-11-02 | — | — | CN | disclosed |
| WO-2003045400-A1 | COMBINATION OF AN IL-1/18 INHIBITOR WITH A TNF INHIBITOR FOR THE TREATMENT OF INFLAMMATION | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-0964849-B1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1270554-A1 | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1270565-A1 | 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives | PFIZER INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6433009-B1 | TREATMENT OF AUTOIMMUNE, CARDIOVASCULAR, NERVOUS SYSTEM, GASTROINTESTINAL, RESPIRATORY SYSTEM, AND VIRAL DISORDERS; ANTIDIABETIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANTIDEPRESSANT AGENTS | PFIZER INC | 2002-08-13 | — | — | US | disclosed |
| EP-1214087-A1 | COMBINATION TREATMENT WITH IL-1RA AND COMPOUNDS THAT INHIBIT IL-1 PROCESSING AND RELEASE | Pfizer Products Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019390-A1 | COMBINATION TREATMENT WITH IL-1RA AND DIARYL SULPHONYL UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| US-6166064-A | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112159-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | NLRP3 1/4885CA2 2434/4885 |
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | NLRP3 1/4885CA2 3818/4885 |
| US-20030143230-A1 | Combination of an IL-1/18 inhibitor with a TNF inhibitor for the treatment of inflammation | IL1A, IL1B, IL18 | NLRP3 119/4885CA2 4147/4885 |
| US-20240400502-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | NLRP3 1/4885CA2 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.